Ambulatory Blood Pressure Changes Following Initiation of Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease

Background/Objectives: Cardiovascular autonomic dysfunction is common in advanced Parkinson’s disease (PD), but 24-h ambulatory blood pressure profiles after initiation of continuous subcutaneous foslevodopa/foscarbidopa have not been fully characterized. Methods: In this retrospective, single-center exploratory longitudinal study, 21 patients underwent ambulatory blood pressure monitoring at baseline, during the first week after maintenance-dose optimization, and at 1 and 6 months. Results: The prevalence of nocturnal hypertension differed across visits (90.5% at baseline; 68.4% at 6 months; global p = 0.033). Nighttime systolic and diastolic blood pressure were lower at 6 months, with significant global differences (p = 0.042 and p = 0.021), whereas daytime measures did not differ significantly. Significant global differences were found for 24-h systolic blood pressure standard deviation, coefficient of variation, and average real variability (p = 0.007, p = 0.037, and p = 0.010). Nocturnal exposure to mean arterial pressure > 100 mmHg decreased, whereas no statistically significant increases in exposure to mean arterial pressure < 65 mmHg or in the prevalence of orthostatic hypotension were detected. The prevalence of supine hypertension differed across visits (p = 0.048). Conclusions: Follow-up was characterized by lower nocturnal hypertensive burden and reduced systolic blood pressure variability, without a group-level signal of worsening orthostatic responses. Larger controlled studies are required to confirm these exploratory findings.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-11-19
DOI
https://doi.org/10.3390/biomedicines14112680
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ambulatory Blood Pressure Changes Following Initiation of Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease

Halina Bartosik-Psujek, Izabella Tomaszewska-Lampart, Marek Biesiadecki, Katarzyna Koszarska et al.
Biomedicines
Parkinson's Disease Mechanisms and Treatments
article

Ambulatory Blood Pressure Changes Following Initiation of Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease

Halina Bartosik-Psujek, Izabella Tomaszewska-Lampart, Marek Biesiadecki, Katarzyna Koszarska, Karolina Głowacka, Aleksandra Kostek
article en

Abstract

Background/Objectives: Cardiovascular autonomic dysfunction is common in advanced Parkinson’s disease (PD), but 24-h ambulatory blood pressure profiles after initiation of continuous subcutaneous foslevodopa/foscarbidopa have not been fully characterized. Methods: In this retrospective, single-center exploratory longitudinal study, 21 patients underwent ambulatory blood pressure monitoring at baseline, during the first week after maintenance-dose optimization, and at 1 and 6 months. Results: The prevalence of nocturnal hypertension differed across visits (90.5% at baseline; 68.4% at 6 months; global p = 0.033). Nighttime systolic and diastolic blood pressure were lower at 6 months, with significant global differences (p = 0.042 and p = 0.021), whereas daytime measures did not differ significantly. Significant global differences were found for 24-h systolic blood pressure standard deviation, coefficient of variation, and average real variability (p = 0.007, p = 0.037, and p = 0.010). Nocturnal exposure to mean arterial pressure > 100 mmHg decreased, whereas no statistically significant increases in exposure to mean arterial pressure < 65 mmHg or in the prevalence of orthostatic hypotension were detected. The prevalence of supine hypertension differed across visits (p = 0.048). Conclusions: Follow-up was characterized by lower nocturnal hypertensive burden and reduced systolic blood pressure variability, without a group-level signal of worsening orthostatic responses. Larger controlled studies are required to confirm these exploratory findings.

BiomedicinesVol. 14(11)
University of Rzeszów (PL)
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon